Compare BLIN & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLIN | XBIO |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 7.5M |
| IPO Year | 2018 | N/A |
| Metric | BLIN | XBIO |
|---|---|---|
| Price | $0.85 | $3.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.62 | N/A |
| AVG Volume (30 Days) | ★ 31.9K | 25.8K |
| Earning Date | 02-12-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,568,000.00 | N/A |
| Revenue This Year | $22.67 | $2.81 |
| Revenue Next Year | $21.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $1.90 |
| 52 Week High | $2.22 | $13.93 |
| Indicator | BLIN | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 58.57 |
| Support Level | $0.69 | $2.64 |
| Resistance Level | $0.87 | $3.12 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 12.51 | 62.20 |
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.